Myriad myPlan™ Lung Cancer measures
expression levels of critical cell cycle genes. Combined with pathologic
tumor stage, the result is correlated with the 5-year risk of lung cancer
death—guiding physicians in making
chemotherapy decisions for early-stage patients.
Myriad myPath™ Melanoma is a unique molecular test created specifically for difficult-to-diagnose melanoma cases. By analyzing 23 genes, the test provides valuable additive molecular information unavailable from any other method for a more informed diagnosis.
Prolaris® measures the expression level of genes involved with tumor proliferation, providing physicians with unique additional information about a patient’s prostate cancer prognosis and may be used with other clinical factors - providing valuable insight into treatment planning.
Myriad ResultsNow™ electronically delivers Myriad test results. Easily view your patient’s test results from anywhere there is an internet connection. View from your office, home, on any hand-held device.
A healthcare provider may include a Letter of Medical Necessity (LMN) with a pre-authorization request, claim submission, or appeal to facilitate the insurance review process for the benefit of the patient. Our experience with insurance companies is such that we encourage healthcare providers to cover as many of the following points as possible that are applicable to the patient:
Explanation that the requested genetic test has been ordered by a physician
Explanation of the medical necessity for the test requested
If family history is cited, give as much family history as possible, including
specifics about relationship to patient, cancer site, age of cancer diagnosis
(alternatively, a detailed three-generation pedigree that contains this
information could be attached and referred to in the body of the letter)
Patient's diagnosis and prognosis, including age of onset and specific location
Explanation that the genetic test is recognized as appropriate for inclusion in
this patient's treatment regimen
Treatment plan, including specific statements about anticipated impact of the
genetic test on the medical management of patient.
We remind you to read through the entire letter to make sure it makes sense for each patient.
Please call Myriad Customer Service (800) 469-7423, prompt “0” if you need help or have any questions.
BRACAnalysis, COLARIS, COLARIS AP, MELARIS, Myriad myPath, myPlan, myRisk, TheraGuide, PREZEON, PANEXIA, and
Prolaris are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions